Core Viewpoint - *ST Suwu's stock price fell sharply due to the chairman's investigation for information disclosure violations, raising concerns about the company's future and potential delisting risks [1][3]. Group 1: Company Investigation and Financial Health - On May 14, *ST Suwu announced that its chairman, Qian Qunshan, is under investigation by the China Securities Regulatory Commission (CSRC) for suspected information disclosure violations [1]. - The company has been under investigation since February 27 for similar allegations, and it has not yet received a conclusive opinion from the CSRC [3]. - The accounting firm, Zhongxing Caiguanghua, issued an audit report for 2024 stating it could not express an opinion due to significant overdue receivables totaling 1.062 billion yuan, with 1.027 billion yuan overdue [3]. - The company also reported that 769 million yuan of its funds were occupied by related parties, increasing the risk of delisting [3]. Group 2: Business Strategy and Performance - Since its establishment in 1994, *ST Suwu has diversified into pharmaceuticals, chemicals, and real estate, with a recent focus on the medical aesthetics sector [4]. - The company achieved profitability after two years of losses, with revenues of 2.026 billion yuan in 2022 and 2.240 billion yuan in 2023, and a projected net profit of 55 to 80 million yuan for 2024, largely due to sales of the "Tian Yan Needle" [4]. - The sales revenue from the "Tian Yan Needle" reached 195 million yuan, with a gross margin of 82.89%, contributing significantly to the company's turnaround [4]. Group 3: Market Competition and Challenges - Despite the turnaround, *ST Suwu faces significant cash flow pressure, with cash reserves dropping from 1.152 billion yuan in 2024 to 168 million yuan in Q1 2025, against short-term borrowings of 1.304 billion yuan [5]. - The medical aesthetics market is highly competitive, with eight similar products already approved in China, posing a risk to *ST Suwu's market position [5]. - The exclusive sales rights for the "Tian Yan Needle" will last until 2032, but competition from other companies, including a major player acquiring the parent company of the product, could impact future sales [5][6].

Core Viewpoint - Jiangsu Wuzhong Pharmaceutical Development Co., Ltd. is facing multiple negative events, including an investigation by the China Securities Regulatory Commission (CSRC) for information disclosure violations, a lawsuit against its wholly-owned subsidiary for tax fraud, and significant financial issues, leading to a sharp decline in investor confidence and stock price [1][2][5]. Group 1: Regulatory and Legal Issues - The chairman of Jiangsu Wuzhong, Qian Qunshan, is under investigation by the CSRC for suspected information disclosure violations, which has raised concerns about the company's future [1][2]. - The company’s wholly-owned subsidiary, Jiangsu Wuzhong Import and Export Co., was sued for allegedly assisting in tax fraud, with the involved amount reaching 242 million yuan [2][3]. - The company has been issued a "non-standard" audit opinion for its annual report, and its stock has been marked with risk warnings, indicating potential delisting [3][4]. Group 2: Financial Performance and Market Reaction - Jiangsu Wuzhong's stock price has plummeted to 2.38 yuan per share, reflecting a cumulative decline of 73.44% from February 27 to May 15 [5]. - The company reported a net profit loss for several consecutive years, with figures showing a decline from 2018 to 2023, although a recent entry into the medical aesthetics market has provided some revenue boost [4][5]. - The medical aesthetics business, particularly the introduction of the AestheFill product, has shown promising growth, generating 113 million yuan in revenue in the first quarter of 2024, despite overall revenue decline in other segments [4]. Group 3: Internal Management and Future Outlook - The series of negative announcements has revealed significant internal control issues within Jiangsu Wuzhong, raising uncertainties about its future development [4]. - The company needs to enhance its corporate governance and restore investor confidence while seeking new growth points in its pharmaceutical segment to recover from its current low performance [5].

Group 1 - Feilong Co., Ltd. received a project designation notification letter from a well-known domestic automobile brand, becoming a supplier for a water-side thermal management module, with expected sales revenue during the lifecycle meeting disclosure standards [1] - Hanchuan Intelligent's controlling shareholder received a warning letter from Jiangsu Securities Regulatory Bureau for failing to timely disclose a share pledge contract, which may affect the company's control and stock price [2] - Vanke A completed the redemption of the "20 Vanke 04" corporate bonds, with a redemption amount of 1.5 billion yuan and interest payment of 51.75 million yuan [3][4] Group 2 - China Shenhua reported a 4% year-on-year decline in coal sales volume for April, totaling 35.6 million tons, and a 3.9% decrease in commodity coal production [5] - Shaanxi Black Cat plans to increase capital by 600 million yuan for its wholly-owned subsidiary Xinjiang Black Cat Coal Industry to enhance its capital strength [6][7] - China National Aviation reported an 8.6% year-on-year increase in passenger turnover for April, with a 5.3% increase in passenger capacity [8][9] Group 3 - Huabei Pharmaceutical's subsidiary received approval for clinical trials of a recombinant tetanus vaccine, which is a new generation vaccine with better safety and immunogenicity [10] - China Chemical's subsidiary received a lawsuit notice related to a securities false statement liability dispute [11] - China Metallurgical Group reported a 24.9% year-on-year decline in new contract value for January to April, totaling 308.4 billion yuan [13] Group 4 - Zhongmei Energy reported a 5.8% year-on-year decline in commodity coal sales for April, totaling 21.1 million tons [14] - Huangma Technology announced a plan to reduce holdings of up to 6.26 million shares due to personal funding needs [15] - Aiyingshi proposed a cash dividend of 2.53 yuan per 10 shares for the fiscal year 2024 [16] Group 5 - Shengyi Technology's executives plan to reduce their holdings by a total of 1.49 million shares [17] - CanSino's inhaled tuberculosis vaccine received clinical trial approval in Indonesia [18] - Beidouxingtong completed the acquisition of 51% of Shenzhen Tianli Automotive Electronics Technology Co., Ltd. [19] Group 6 - Spring Airlines reported a 12.29% year-on-year increase in available capacity for April, with a total of 4.73 billion ton-kilometers [20] - Dongya Pharmaceutical's raw material drug received registration certification in South Korea [21] - Shandong Steel plans to establish a sales subsidiary with a registered capital of 20 million yuan [22] Group 7 - Caida Securities appointed Hu Hengsong as the executive vice president [23] - Aibulu's vice president resigned due to personal career planning [24] - *ST Jinguang's stock price surged amid a warning of delisting risk [25] Group 8 - Yunnan Energy Investment plans to implement a 600,000 tons/year salt production energy-saving and carbon reduction project with a total investment of 448 million yuan [27] - Hanyu Group's executives plan to reduce their holdings due to personal funding needs [28] - Jiangsu Boyun's shareholders plan to reduce their holdings by up to 971,300 shares [29] Group 9 - Hainan Airport signed a cooperation agreement with Harbin Institute of Technology (Shenzhen) to establish a joint laboratory [32] - Xiamen Tungsten New Energy plans to acquire 47% of Ganzhou Haopeng Technology Co., Ltd. [33] - Dongfang Materials announced a change in controlling shareholder due to judicial auction of shares [34] Group 10 - Jingyuan Environmental Protection's executives plan to reduce their holdings by a total of 1.176% of the company's shares [35] - China Pacific Insurance reported a 10.4% year-on-year increase in original insurance premium income for the first four months [36] - ST United is planning a major asset restructuring and has suspended trading [37] Group 11 - *ST Suwu's chairman received a notice of investigation for suspected information disclosure violations [39] - Huagong Technology's subsidiary plans to establish a joint venture [40] - Qibin Group terminated the purchase of 28.78% equity in its subsidiary [41] Group 12 - Huakang Clean signed a construction contract worth 143 million yuan with Dengfeng City General Hospital [42] - Kanghong Pharmaceutical received approval for clinical trials of a drug for postpartum depression [43] - Shengjing Micro plans to repurchase shares worth between 30 million and 50 million yuan [44] Group 13 - Shenghe Resources' subsidiary plans to acquire 100% of Peak Rare Earths Limited for 158 million Australian dollars [45] - Sinopec's controlling shareholder increased its stake by 302 million H-shares, amounting to HKD 1.232 billion [46] - Mingyang Circuit plans to repurchase shares worth between 15 million and 25 million yuan [47] Group 14 - China Oil Engineering's subsidiary won a project in Iraq worth approximately 11.538 billion yuan [48] - Chaojie Co., Ltd. announced the termination of a share transfer agreement [49]

江苏吴中医药发展股份有限公司 股票交易异常波动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要风险提示： 江苏吴中医药发展股份有限公司（以下简称"公司"）股票连续三个交 易日内收盘价格跌幅偏离值累计超过 12%，属于股票交易异常波动的情形。 证券代码：600200 证券简称：*ST苏吴 公告编号：临2025-039 公司已被中国证券监督管理委员会(以下简称"中国证监会")立案调查， 目前公司尚未收到就上述立案调查事项的结论性意见或决定，若后续经中国证监 会行政处罚认定的事实，触及《上海证券交易所股票上市规则》规定的重大违法 强制退市情形，公司股票将被实施重大违法强制退市。具体内容详见公司于 2025 年 2 月 27 日披露的《关于收到中国证券监督管理委员会立案告知书暨风险提示 公告》（公告编号：临 2025-007）。请投资者理性投资，注意投资风险。 中兴财光华会计师事务所（特殊普通合伙）对公司 2024 年度出具了无法 表示意见的财务报告审计报告和内部控制审计报告；公司在 2024 年度审计期间， 经公司自查， ...

Core Viewpoint - Jiangsu Wuzhong has faced multiple negative events since 2025, including regulatory scrutiny and financial difficulties, leading to its stock being placed on risk warning status and potential delisting [1][3][5]. Group 1: Regulatory Issues - The chairman of Jiangsu Wuzhong, Qian Qunshan, received a notice from the China Securities Regulatory Commission (CSRC) regarding an investigation for suspected violations of information disclosure laws [1]. - The company has been under investigation since February 27, 2025, for similar allegations, with the CSRC deciding to initiate a case against it [3]. - A subsidiary's former legal representative was prosecuted for involvement in fraudulent activities related to export tax rebates [3]. Group 2: Financial Performance - In 2024, Jiangsu Wuzhong reported a revenue of 1.599 billion yuan, a year-on-year decrease of 28.64%, but achieved a net profit of 70.48 million yuan, marking a turnaround from losses [4]. - The pharmaceutical segment generated revenue of 1.229 billion yuan, down 33.19% year-on-year, while the medical beauty sector saw a significant increase in revenue to 330 million yuan, up 4225.65% [4]. Group 3: Corporate Governance and Internal Control - Despite a slight improvement in financial performance, Jiangsu Wuzhong has revealed serious internal control issues, pushing the company closer to delisting [5]. - The controlling shareholder, Suzhou Wuzhong Investment Holdings, held a 17.24% stake in the company as of the first quarter of 2025 [6].

Core Viewpoint - The article discusses the ongoing regulatory issues faced by *ST Suwu, including the investigation of its chairman by the China Securities Regulatory Commission (CSRC) and the implications for the company's financial health and operations [2][3]. Group 1: Regulatory Issues - The chairman of *ST Suwu, Qian Qunshan, is under investigation by the CSRC, which has issued a notice of investigation. This investigation is focused solely on the chairman and is not expected to significantly impact the company's daily operations [3]. - In February 2024, *ST Suwu received a notice from the CSRC regarding suspected violations of information disclosure laws, which could lead to severe penalties, including potential delisting [3][8]. Group 2: Financial Performance - For the year 2024, *ST Suwu reported a revenue of 1.599 billion yuan, a decrease of 28.64% year-on-year, and a net profit attributable to shareholders of 70.48 million yuan [6]. - The company has been issued a non-standard audit opinion due to issues related to the misuse of funds by related parties, with 769 million yuan reported as misappropriated and not returned [6]. Group 3: Business Operations - *ST Suwu operates in the pharmaceutical sector through its subsidiary, Jiangsu Wuzhong Pharmaceutical Group, focusing on drug research, production, and sales, with key products in various therapeutic areas [4]. - The company aims to develop a dual-driven strategy focusing on both pharmaceutical and medical beauty sectors, leveraging opportunities in the health industry to enhance market competitiveness [6]. Group 4: Legal and Financial Risks - The company faces additional legal challenges, including a lawsuit against its subsidiary's former legal representative for alleged fraud related to export tax rebates, with the first court hearing scheduled for April 2025 [7]. - Due to overdue loans, some of the company's bank accounts have been frozen, which may further impact its financing capabilities and business operations [7].

本公司董事会及董事会全体成员保证公告内容不存在虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实、准确和完整承担法律责任。 证券代码：600200 证券简称：*ST 苏吴 公告编号：临 2025-038 江苏吴中医药发展股份有限公司 关于公司董事长收到立案告知书的公告 2025 年 5 月 15 日 江苏吴中医药发展股份有限公司（以下简称"公司"）收到公司董事长钱群 山先生通知，其于近日收到中国证券监督管理委员会（以下简称"中国证监会"） 出具的《立案告知书》（编号：证监立案字 0392025008 号），因涉嫌信息披露 违法违规，根据《中华人民共和国证券法》《中华人民共和国行政处罚法》等法 律法规，中国证监会决定对其立案。 本次立案仅针对董事长个人，不会对公司日常经营活动产生重大影响。立案 调查期间，公司董事长将积极配合中国证监会的调查工作。 公司将持续关注上述事项的进展情况，并严格按照有关法律法规的规定和要 求，及时履行信息披露义务。公司所有信息均以在《上海证券报》《中国证券报》 以及上海证券交易所网站（www.sse.com.cn）刊登的正式公告为准，敬请广大投 资者谨慎投资，注意风险。 董事会 特此 ...

本公司董事会及董事会全体成员保证公告内容不存在虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实、准确和完整承担法律责任。 重要风险提示： 公司于 2025 年 2 月 27 日披露了《江苏吴中医药发展股份有限公司关于收到 中国证券监督管理委员会立案告知书暨风险提示公告》（公告编号：临 2025-007）， 证券代码：600200 证券简称：*ST 苏吴 公告编号：临 2025-037 江苏吴中医药发展股份有限公司 关于立案调查进展暨风险提示公告 若后续经中国证监会行政处罚认定的事实，触及《上海证券交易所股票上市 规则》规定的重大违法强制退市情形，公司股票将被实施重大违法强制退市。请 投资者理性投资，注意投资风险。 公司所有信息均以在上海证券交易所网站（www.sse.com.cn）和《上海证券 报》《中国证券报》刊登的正式公告为准，敬请广大投资者谨慎投资，注意风险。 特此公告。 江苏吴中医药发展股份有限公司 董事会 2025 年 5 月 15 日 江苏吴中医药发展股份有限公司(以下简称"公司")已被中国证券监督 管理委员会(以下简称"中国证监会")立案调查，目前公司尚未收到就 上述立案调查事项的结论性意见 ...

*ST苏吴（600200）公告，公司已被中国证监会立案调查，目前尚未收到就上述立案调查事项的结论性 意见或决定。若后续经中国证监会行政处罚认定的事实，触及《上海证券交易所股票上市规则》规定的 重大违法强制退市情形，公司股票将被实施重大违法强制退市。公司股票已被实施退市风险警示(*ST) 叠加其他风险警示。 ...

金融界消息 截至2025年5月14日收盘，*ST苏吴（600200）报收于2.51元，下跌4.92%，换手率3.1%，成 交量22.04万手，成交金额5568.48万元。 来源：金融界 资金流向方面，今日主力资金净流出1557.82万元，占比成交额27.98%。其中，超大单净流出925.25万 元、占成交额16.62%，大单净流出632.57万元、占成交额11.36%，中单净流出流入0.31万元、占成交额 0.01%，小单净流入1557.51万元、占成交额27.97%。 天眼查商业履历信息显示，江苏吴中医药发展股份有限公司，成立于1994年，位于苏州市，是一家以从 事医药制造业为主的企业。企业注册资本71215.1832万人民币，实缴资本12279.5762万人民币。公司法 定代表人为钱群山。 通过天眼查大数据分析，江苏吴中医药发展股份有限公司共对外投资了13家企业，参与招投标项目5 次，知识产权方面有商标信息46条，专利信息2条，此外企业还拥有行政许可9个。 *ST苏吴最新一期业绩显示，截至2025一季报，公司营业总收入3.17亿元、同比减少25.44%，归属净利 润7031.79万元，同比减少1489.9 ...